Lab services company Charles River Laboratories (NYSE:CRL) reported Q1 CY2025 results exceeding the market’s revenue expectations , but sales fell by 2.7% year on year to $984.2 million.

Shares of lab services company Charles River Laboratories (NYSE:CRL) jumped 17.3% in the afternoon session after the company reported strong first quarter 2025 results which significantly beat ...

and initiating a strategic review to enhance long-term shareholder value. Price Action: CRL stock is up 22.9% at $141.83 at the last check Wednesday.

Design agency Koto has collaborated with online retailer Amazon's design team Amazon XCM in a rebrand of the company's distinct smile logo, while simplifying the identity of over 50 Amazon sub-brands.

CEO Jim Foster addressed the FDA's recent announcement to accelerate validation and adoption of New Approach Methods (NAMs), emphasizing that Charles River supports this vision and has been ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Toxicology is the scientific discipline concerned with the detection, evaluation and prevention of the toxic effects of substances that humans are exposed to. It has a key role in the development ...

Charles River Laboratories International, Inc. is an early-stage contract research company, which provides essential products and services to help pharmaceutical and biotechnology companies ...

The FDA delivered a blow to Spero's hopes of bringing the carbapenem to market in a complete response letter (CRL) delivered this week, which said another trial would be required to support approval.